PMC Weekly Review - September 25, 2015
Looking back over the recent bull market, it is hard to ignore the high-flying Biotechnology industry. In fact, the NASDAQ Biotechnology Index is up more than 400% since it began its rally in early 2009, and is on pace to outperform the broader equity market for a fifth consecutive year. The industry that uses biologic systems to develop products with the goal of ultimately improving lives and health has indeed benefited from many successful innovations over the past few years. Biotech’s global market capitalization has surged to over $1 trillion, driven by record breaking IPO issuance, merger and acquisition activity, and new drug approvals. This growth means it is an increasingly significant component of indices and portfolios, and according to Barron’s, Biotech’s weight has reached an all-time high in most benchmarks. This upward momentum has sparked discussions amongst investors over the past few months about a potential bubble burst similar to Information Technology in the early 2000’s. Recent market volatility demonstrates how susceptible the industry is to large price fluctuations. Others suggest that the sector remains fundamentally strong despite all the noise, and attractive opportunities still exist. One thing is certain: Biotech’s importance should not be overlooked, given its increased allocation in equity indices, and investors should scrutinize carefully their holdings in this space.
Those who believe Biotech is poised for significant declines emphasize how pricey the sector has become, especially since many of these companies are currently unprofitable. Data from The Wall Street Journal shows more than half of Biotech companies in the NASDAQ Biotechnology Index are losing money, and many investors consider these stock prices to be inflated and their momentum unsustainable. The iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) lists a P/E ratio of over 28x, which is not excessively expensive for a growth sector. However, this P/E figure excludes companies that do not earn a profit; if the multiple were adjusted to include these stocks, it would skyrocket to over 130x, which certainly is pricey. Based on this metric, relative valuations appear to be stretched, which could take a toll on merger and acquisition activity moving forward. On Tuesday, Severin Schwan, CEO of the giant Swiss drug maker Roche, stated “this whole segment is overvalued”, attractive purchase opportunities are “far, far away” from fundamental value, and expressed concern about the potential for a “collapse”. The diminishing M&A tailwinds, coupled with overvalued P/E multiples, have set the scene for a challenging environment, and one that potentially could burst the Biotech bubble.
Despite the pullback over the past several weeks, bulls are optimistic there is still room for growth in Biotech, and the volatility will not trigger a widespread crash in the industry. Although some compare the Biotech run-up to that of past market bubbles, others highlight this rally as being nowhere near as extreme as were Information Technology in the late 1990’s or Homebuilders in the early 2000’s. Illustrated by USA Today, the Biotech rally reached 400% in July, but at their peaks, IT and Homebuilders increased more than 1100% and 800%, respectively, before their subsequent, violent selloffs. From a technical perspective, Biotech is the number one relative strength industry (in relation to the S&P 500). According to the widely followed technical analyst Thomas Dorsey, of Dorsey Wright & Associates, “Everything still suggests the Biotech sector still has the strength, not just in itself, but on a relative basis.” Although the recent decline in Biotech was slightly more severe than the broader market, it followed a similar trajectory. Furthermore, in 2015 the S&P 500 Biotech (NYSE: XBI) is still outpacing the S&P 500 by a wide margin, as of market close Thursday: up nearly 17% versus down over 6% in the S&P 500.
No clear conclusions can be drawn about the short-term fate of Biotech, but it is displaying characteristics of a fragile industry. The NASDAQ Biotechnology Index* plunged 4.5% Monday, and was down a total of over 8.5% for the week (as of Thursday’s close) amidst a relatively slow week of major economic news after presidential candidate Hilary Clinton tweeted her plan to outlaw certain pricing strategies prevalent in the industry. A good deal of speculation surfaced about whether this may be the beginning of the end for the Biotech rally, while others are calling it merely noise, as fundamentals appear solid. Given the looming uncertainty, investors need to recognize that as Biotech has become a more substantial part of the global equity landscape, it carries greater risks of a potential bubble burst.
The information, analysis, and opinions expressed herein are for general and educational purposes only. Nothing contained in this weekly review is intended to constitute legal, tax, accounting, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. All investments carry a certain risk, and there is no assurance that an investment will provide positive performance over any period of time. An investor may experience loss of principal. Investment decisions should always be made based on the investor’s specific financial needs and objectives, goals, time horizon, and risk tolerance. The asset classes and/or investment strategies described may not be suitable for all investors and investors should consult with an investment advisor to determine the appropriate investment strategy. Past performance is not indicative of future results.
Information obtained from third party sources are believed to be reliable but not guaranteed. Envestnet|PMC™ makes no representation regarding the accuracy or completeness of information provided herein. All opinions and views constitute our judgments as of the date of writing and are subject to change at any time without notice.
Investments in smaller companies carry greater risk than is customarily associated with larger companies for various reasons such as volatility of earnings and prospects, higher failure rates, and limited markets, product lines or financial resources. Investing overseas involves special risks, including the volatility of currency exchange rates and, in some cases, limited geographic focus, political and economic instability, and relatively illiquid markets. Income (bond) securities are subject to interest rate risk, which is the risk that debt securities in a portfolio will decline in value because of increases in market interest rates. Exchange Traded Funds (ETFs) are subject to risks similar to those of stocks, such as market risk. Investing in ETFs may bear indirect fees and expenses charged by ETFs in addition to its direct fees and expenses, as well as indirectly bearing the principal risks of those ETFs. ETFs may trade at a discount to their net asset value and are subject to the market fluctuations of their underlying investments. Investing in commodities can be volatile and can suffer from periods of prolonged decline in value and may not be suitable for all investors. Index Performance is presented for illustrative purposes only and does not represent the performance of any specific investment product or portfolio. An investment cannot be made directly into an index.
Alternative Investments may have complex terms and features that are not easily understood and are not suitable for all investors. You should conduct your own due diligence to ensure you understand the features of the product before investing. Alternative investment strategies may employ a variety of hedging techniques and non-traditional instruments such as inverse and leveraged products. Certain hedging techniques include matched combinations that neutralize or offset individual risks such as merger arbitrage, long/short equity, convertible bond arbitrage and fixed-income arbitrage. Leveraged products are those that employ financial derivatives and debt to try to achieve a multiple (for example two or three times) of the return or inverse return of a stated index or benchmark over the course of a single day. Inverse products utilize short selling, derivatives trading, and other leveraged investment techniques, such as futures trading to achieve their objectives, mainly to track the inverse of their benchmarks. As with all investments, there is no assurance that any investment strategies will achieve their objectives or protect against losses.
Neither Envestnet, Envestnet|PMC™ nor its representatives render tax, accounting or legal advice. Any tax statements contained herein are not intended or written to be used, and cannot be used, for the purpose of avoiding U.S. federal, state, or local tax penalties. Taxpayers should always seek advice based on their own particular circumstances from an independent tax advisor.
© 2015 Envestnet. All rights reserved.